La différenciation terminale des lymphocytes B qui se déroule dans les centres germinatifs des organes lymphoïdes secondaires est l’étape ultime de la réponse T dépendante et aboutit à la production de plasmocytes (PC) à longue durée de vie qui sécrètent des anticorps hautement affins spécifiques de l’antigène et caractéristiques de la réponse immune adaptative. La transition d’une cellule B naïve vers un PC est gouvernée par un réseau de régulation génique bien décrit et est largement influencée par l’intégration de stimuli externes qui contrôlent le devenir des cellules B tels que l’interaction BCR-antigène et les cytokines produites par les cellules T. La stimulation précoce des lymphocytes B humains activés par IL-2, induit la différenciation en PC via une signalisation ERK prolongée entraînant la baisse d’expression de BACH2, un facteur de transcription clef des cellules B. La répression transitoire de BACH2 est suffisante pour déclencher la différenciation en plasmablastes en l’absence d’IL-2, suggérant ainsi qu’il joue un rôle de « verrou moléculaire » de la différenciation en PC. Il est à noter que cette répression forcée de BACH2 aboutit à la production de plasmablastes caractérisés par un phénotype lymphoplasmocytaire. Ce travail de recherche s’est focalisé sur la caractérisation des mécanismes moléculaires régulant l’expression de BACH2 via la voie de signalisation ERK induite par IL-2. Nous avons identifié ELK-1 comme un médiateur de la répression de BACH2 par la voie IL-2/ERK, comme l’atteste sa capacité à se lier avec un élément de régulation d’un enhancer localisé dans l’intron 1 de BACH2, induisant ainsi la répression de l’enhancer et déverrouillant la différenciation en PC. La caractérisation de cet enhancer de BACH2 a confirmé qu’il est régulé de manière dynamique au cours de la différenciation terminale B et qu’il est localisé dans une région sujette aux mutations suggérant qu’il pourrait être impliqué dans la lymphomagenèse. / The terminal differentiation of B cells, which takes places within germinal centres of secondary lymphoid organs, is the ultimate step of a T cell dependent response and results in the generation of long-lived plasma cells (PCs) that secrete protective, antigen-specific, high-affinity antibodies as part of adaptive immunity. The transition of a naive B cell into a PC is governed by a well-characterised gene regulatory network and is heavily influenced by the integration of externally received signals, including BCR-antigen binding and T cell help, such as cytokines which guide B cell fate. The early IL-2 priming of human primary activated B cells triggers PC differentiation through sustained ERK signalling resulting in the down regulation of B cell transcription factor BACH2. Transient BACH2 repression is sufficient to trigger plasmablast differentiation in the absence of IL-2 suggesting that it acts as a key lock of PC differentiation. Importantly, this enforced BACH2 repression results in the generation of plasmablasts with a lymphoplasmacytic phenotype. The focus of this thesis was to characterise the molecular mechanisms regulating BACH2 expression via the IL-2 ERK transduction pathway. We identify ELK-1 as the mediator of IL-2 ERK induced BACH2 downregulation as it binds to a regulatory enhancer element located within intron 1 of BACH2 instigating its repression and unlocking the PC programme triggering differentiation. The characterisation of this BACH2 enhancer confirms that it is dynamically regulated during PC differentiation and is located within a region targeted for mutation suggesting that it may have a potential role in lymphomagenesis.

Les pénicillines font partie des molécules chimiques les plus fréquemment impliquées dans l’allergie médicamenteuse. Selon l’hypothèse de l’haptène, les molécules chimiques de petite taille doivent se lier aux protéines pour êtres immunogènes. Cependant, très peu est connu sur le processus d’immunisation des patients aux bioconjugués pénicilline-protéine. Notre groupe a récemment synthétisé des bioconjugués albumine sérique humaine-benzylpénicilline (HSA-BP) et a démontré l'existence de lymphocytes T CD4+ naïfs spécifiques du bioconjugué HSA-BP chez des donneurs sains. L'objectif de ce travail de thèse est d'identifier des séquences peptidiques issus de la HSA hapténisées avec la BP, impliquées dans l’activation des cellules T naïves ainsi que l’immunisation des patients allergiques et par conséquent les manifestations cliniques. Notre stratégie combine la spectrométrie de masse, la modélisation moléculaire et le criblage virtuel, la synthèse chimique orientée et la validation biologique sur des lignées de cellules T de longues durées chez les donneurs sains, et à l’aide du test de transformation lymphocytaire ainsi que les lignées de cellules T de courte durée chez les patients allergiques. Cette étude a permis: (1) l’identification des résidus lysine présents sur la HSA hapténisés par la BP par spectrométrie de masse, (2) la sélection par une approche in silico des peptides de 15-mer potentiellement immunogènes, (3) la synthèse orientée de ces peptides-BP à l’aide d’un monomère lysine-BP, (4) l’identification des épitopes reconnus par les cellules T naïves de donneurs sains, (5) la validation de deux épitopes situés sur les lysines 159 et 525 chez les patients allergiques aux pénicillines et (6) confirmation de la HSA comme un bon modèle pour l’hapténisation de la BP. / Penicillins are among the most prevalent drug-inducing allergy. According to the hapten hypothesis small chemical molecules needs to bind to proteins to be immunogenic. However, little is known on the process of patients immunization to penicillin-protein conjugates. Our group has recently synthesized benzylpenicillin-human serum albumin (BP-HSA) bioconjugate and demonstrated the existence of naïve CD4+ T lymphocytes specific to BP-HSA in healthy donors. The objective of this work was to identify peptides sequences from HSA haptenized with BP involved in naïve T-cells activation, immunization of patients and consequently the clinical manifestations. Our strategy combines mass spectrometry, molecular modeling and virtual screening, chemical oriented synthesis and biological validation using long-term T-cell lines in healthy donors and the lymphocyte transformation test as well as short-term T-cell lines in allergic patients. This study allowed: (1) the identification of lysine residues involved in the BP binding to HSA using mass spectrometry, (2) the selection of BP-peptides containing the lysine residues likely to induce immune response using an in silico approach, (3) the synthesis of the selected BP-15 mer peptide bioconjugates using a lysine-BP monomer, (4) the identification of epitopes recognized by naïve T cells from healthy donors, (5) the validation of two epitopes located on lysines 159 and 525 in allergic patients to penicillins and (6) the confirmation of HSA as a good model for BP haptenation.

T and B-lymphocytes play an important role in an adaptive immune response. Communication between these two cells may result in either a humoral immune response or tolerance. Communication between T and B-lymphocytes involves a number of inducible cell surface molecules on both T and B-lymphocytes. It was the aim of this project to gain a greater understanding of the role of CD40 in the dynamic communication that occurs between naïve T-lymphocytes and resting B-lymphocytes during cognate communication. Because in vivo antigen specific T-lymphocytes are at low frequency, it is difficult to examine antigen-specific naïve T-lymphocytes. Thus, an in vitro system employing naïve antigen-specific T cell receptor (TCR) transgenic T cells and small resting B-lymphocytes that did not express CD40 was devised to examine the role of CD40 in cognate communication between naïve T-lymphocytes and resting B-lymphocytes. Upon recognition of antigen on resting B-lymphocytes that expressed CD40, T-lymphocytes proliferated, expressed the activation antigens CD69 and CD25, and remained responsive to subsequent antigen challenge. In the absence of CD40, resting B-lymphocytes did not induce sustained proliferation or sustained expression of the activation markers CD69 and CD25 on naïve T-lymphocytes, and their recovery was decreased compared to naïve T-lymphocytes that recognized antigen on resting B-lymphocytes that expressed CD40. Naïve T-lymphocytes, however, remained responsive to subsequent antigen challenge after recognition of antigen on resting CD40-/- B-lymphocytes. Recognition of antigen on resting CD40-/- B-lymphocytes also resulted in increased recovery and antigen responsiveness of T-lymphocytes when compared to controls without antigen, The role of CD40 in sustaining activation of naïve T-lymphocytes may be unique to resting B-lymphocytes, since proliferation of naïve T-lymphocytes in response to dendritic cells that did not express CD40 was similar to proliferation of naïve T-lymphocytes in response to dendritic cells that expressed CD40. The mechanism by which CD40 sustained activation of naïve T-lymphocytes was investigated by examining the induction of various costimulatory molecules on resting CD40+/- and CD40-/- B-lymphocytes during cognate interaction with naive T-lymphocytes. Induction of B7-1, upregulation of CD44 and ICAM-1, and sustained but not initial induction of B7-2 required that CD40 be expressed on resting B-lymphocytes. Expression of B7-1 and CD44H was not required for proliferation of naïve T-lymphocytes in response to antigen presented on resting B-lymphocytes. However, sustained expression of B7-2 was crucial for proliferation of naïve T-lymphocytes in response to antigen presented on resting B-lymphocytes.

Les myosites sont des maladies auto-immunes, caractérisées par des atteintes musculaires et extra musculaires. Le diagnostic des myosites peut être difficile et nécessite de l’expertise, afin d’éviter l’administration de thérapie inapproprié. Les mécanismes impliqués au cours des myosites sont peu connus. Notre but était de décrire le profil immunitaire des patients, afin d’identifier des biomarqueurs. Nous avons utilisé un panel de 36 marqueurs pour caractériser les PBMC issus de patients actifs (MIs, SAS anti-Jo1, myopathies anti-SRP et anti-HMGCR) et de sujets sains par cytométrie de masse combiné au « barcoding ». Tout d’abord, nous avons mis au point une procédure technique pour la détection simultanée de cibles extracellulaires et intracellulaires. En utilisant différents outils bio-informatiques, nous avons isolé une fréquence de lymphocytes CD8+T-bet+ > 51.5% comme étant un biomarqueur spécifique de la MIs en comparaison aux autres myosites, avec une sensibilité de 94,74% et une spécificité de 88,46%. De plus, nous avons identifié un profil immunitaire CD8+T-bet+ CD57- activé, potentiellement capable de prolifération et de maintien de mécanismes auto-immuns chez les patients atteints de MIs. Chez les patients anti-Jo1, nous avons observé une dérégulation de l’homéostasie des lymphocytes B, caractérisée par une diminution des lymphocytes B mémoires circulants. La présence de ces derniers dans le muscle des patients suggère qu’ils se nichent dans le muscle afin d’éviter l’action des immunosuppresseurs. Ces travaux ont permis l’identification de biomarqueurs et de phénotypes cellulaires potentiellement impliqués au cours de la MIs et du SAS anti-Jo1. / Myositis is an autoimmune disease characterized by muscular and extra-muscular disorders. In the early stages of the disease, the diagnosis of myositis can be misleading and requires expertise, in order to avoid the administration of inappropriate treatment. The mechanisms involved in these diseases are poorly understood. Our aim was to describe the immune profile specific to each patient group, in order to identify biomarkers that may be useful for diagnosis and management of patients. We used a panel of 36 markers by mass cytometry to characterize PBMCs derived from active patients (sIBM, anti-Jo1 ASyS, anti-SRP and anti-HMGCR myopathies) and healthy subjects. First, we developed and optimized a technical procedure for the simultaneous detection of extracellular and intracellular targets by mass cytometry. Using different bioinformatics tools, we isolated a frequency of CD8 +T-bet + cells > 51.5% as a specific biomarker for sIBM compared to other myositis, with a sensitivity of 94.74% and a specificity of 88. , 46%. In addition, we identified an activated CD8 + T-bet + CD57- immune profile, potentially capable of proliferation and the maintenance of autoimmune mechanisms in patients with sIBM. In anti-Jo1 patients, we observed a dysregulation of B cell homeostasis, characterized by a decrease in circulating memory B cells. The presence of the latter in the muscle of patients suggests that they nest in the muscle to avoid immunosuppressants. This work allowed the identification of a biomarker that could enhance the diagnosis of MIs compared to other myositis and the identification of cells potentially involved during sIBM and anti-Jo1 ASyS.

In this thesis I describe an investigation into the function of the protein Icb-1, a homologue of Themis1 in B cells and monocytes. Themis1 is important for T cell positive and negative selections. Yet its function in T cell development is not clear. Although it shows characteristics of an adaptor protein and involvement in TCR-induced signalling, the exact signalling defects in Themis1-/- T cells remain obscure. Icb-1 is similar to Themis1 in sequence, function and binding partners. It has been studied in human tumour and macrophage cell lines, leading to limited conclusions. Its role in B cells has never been published. Given the link with Themis1, it is of great interest to investigate the function of Icb-1. My study has been focused on the comparison between Icb-1 knockout mice with wild-type controls. I characterised the B cell development in Icb-1-/- mice, either naturally born or produced as mixed adult bone marrow chimeras reconstituted from WT and Icb-1-/- donor cells. I examined the possible compensation and redundancy of Themis1 and Icb-1, by characterising Thems1/Icb-1 double knockout mice. The Ig-HEL mouse models were used to examine the change in B cell repertoire due to negative and positive selections. The mice were challenged with SRBCs or NP-CGG to examine the germinal centre response to foreign antigen when Icb-1 is absent. In vitro stimulation of B cells with soluble and membrane-bound antigens was used to investigate early B cell responses in detail and to give insights into the defects found in in vivo challenges. Finally, I examined the BCR-induced phosphorylation of key signalling molecules and Ca2+ flux in splenic B cells. The study revealed largely normal B cell development with subtle selection impairments, but a partially defected B cell immune response to antigens in Icb-1-/- mice. The marginal zone B cell population was enlarged in the absence of Icb-1, while the positive selection of B1 B cells induced by intracellular self-antigen was impaired. The deficient mice showed a reduction in germinal centre B cell generation. The defects are associated with impaired BCR-induced cell signalling to low abundance and/or low avidity antigens. In particular, Ca2+ flux and Erk1/2 phosphorylation were clearly reduced under certain conditions. The results shine a light on the function of protein Icb-1, and also improve our knowledge of Themis1 and the Themis family. They provide a new avenue of investigation into the regulation of BCR signalling, especially in Ca2+ flux induction and Erk1/2 activation. They also provide insight into how differential signalling is controlled within cells during activation and differentiation in response to antigens that vary in terms of affinity, avidity and frequency.

Plusieurs paramètres participent à l'homéostasie du système immunitaire. On peut notamment citer : la production lymphocytaire (les lymphocytes B dans la moelle osseuse ou les lymphocytes T (LyT) dans le thymus), la prolifération et la survie des lymphocytes périphériques et enfin, la compétition entre les différents clones de lymphocytes ou les différentes populations de lymphocytes pour des ressources limitées en particulier les cytokines. Les mécanismes de régulation homéostatique sont différents selon la sous-population de lymphocyte considérée. Dans le cadre de cette thèse, nous avons étudié le rôle de l'interleukine-7 (IL-7) dans l'homéostasie des lymphocytes et plus particulièrement les lymphocytes T ΑΒ. Disposant de souris surexprimant l'IL-7 dans un état lymphopénique plus ou moins sévère, nous avons pu décortiquer les effets de l'IL-7 sur le développement précoce des LyT et leur survie périphérique. L'analyse du développement précoce des lymphocytes n'a pas révélé d'effet notable de la sur-expression de l'IL-7 sur le développement thymique des LyT. En revanche, une expansion considérable des LyT périphériques a été observée. A partir d'expérience de transferts adoptifs, nous avons montré que l'IL-7 favorisait la prolifération et la survie des LyT périphériques. La quantité d'IL-7 disponible module donc le devenir des LyT présents dans les organes lymphoïdes lors d'un épisode lymphopénique.

Cardiovascular disease, often induced by hypertension, represents a serious health threat, is a primary cause of death worldwide, and results in altered cardiovascular function and ECM composition. Hypertension and related cardiovascular diseases are associated with immune dysfunction. This dissertation investigated the role of T-lymphocytes in modulating cardiovascular function and ECM composition as a possible therapeutic for the treatment of cardiovascular disease. Study one investigated the role of TCR peptide in the development of hypertension and subsequent cardiovascular changes in Balb/C mice. The coadminstration of TCR and L-NAME/8% NaCl reduced the effects of L-NAME/8% NaCl, decreasing blood pressure and crosslinked collagen compared to L-NAME/8% NaCl alone. Study two examined the effects of T-lymphocyte function on cardiovascular structure and function. Adoptive transfer of T-lymphocytes from C57BL/6 WT mice into C57BL/6 SCID mice induced changes in the SCID so that it resembled the WT donor, with increased percent crosslinked collagen and LOX activity. Hemodynamics in the SCID recipient resembled that of the WT and were significantly different from the sham injected SCID. Study three combined aspects of both previous studies. T-lymphocytes were adoptively transferred from hypertensive WT donors into naïve SCID recipients, who developed hypertension and cardiovascular function resembling the hypertensive donor, as well as changes in the ECM, including increased collagen crosslinking. Study four investigated the effect of strain specific T-lymphocyte polarization on hypertension induced cardiac ECM remodeling. Balb/C, C57BL/6 WT, and C57BL/6 SCID had divergent responses to L-NAME induced hypertension. Ventricular stiffness increased in Balb/C, decreased in C57 SCID and did not change in C57 WT; LOX activity changed correspondingly in all groups. The final study examined the effect of TCR administration on LOX activity and collagen crosslinking. Th1 polarization increased LOX activity and crosslinked collagen with corresponding changes in cardiovascular function. In conclusion, modulation of T-lymphocyte function alters cardiovascular function and ECM composition in pathologic and non-pathologic conditions. Immune modulation should be further investigated as a therapeutic for cardiovascular disease.

Le but du travail de recherche présenté dans cette thèse était de déterminer les mécanismes impliqués dans le développement de symptômes neurologiques observés dans une lignée de souris transgénique pour l’expression de la molécule B7.2/CD86. La molécule B7.2 est un des ligands du récepteur CD28 qui transmet des signaux intracellulaires nécessaires à la prolifération des lymphocytes T et au développement de leurs fonctions effectrices. Nos travaux démontrent que ces souris développent spontanément une pathologie démyélinisante auto-immune conséquemment à l’expression transgénique de la molécule B7.2 sur les cellules de la microglie du système nerveux central. Les souris affectées présentent une infiltration de lymphocytes T au niveau du système nerveux central et périphérique proximal et cet infiltrat est prédominé par une population de lymphocytes T CD8[indice supérieur +] mémoires/effectrices. Nos études indiquent que la population de lymphocytes T CD8[indice supérieur +] joue un rôle effecteur dans le développement de la pathologie tandis que la population des lymphocytes T CD4[indice supérieur +] la régulent de façon négative. Nos résultats démontrent également que l’activation des cellules de la microglie survient très tôt lors de la pathogenèse et que cette activation des cellules de la microglie ainsi que le processus de démyélinisation sont entièrement dépendants de la signalisation par le récepteur de l’IFNy. Ce modèle de démyélinisation reflète l’émergence de cellules T autoréactives spécifiques au système nerveux à partir d’un répertoire périphérique polyclonal, un processus immunopathogénique qui se produit possiblement durant la pathogenèse de la sclérose en plaques. De plus, il présente certaines caractéristiques pathologiques similaires à celles de la sclérose en plaques tels que le développement spontané du processus de démyélinisation et de dommages aux axones ainsi qu’une connexité avec l’activité de l’IFNy. Plusieurs données de la littérature suggèrent que les lymphocytes T CD8[indice supérieur +] pourraient jouer un rôle dans les maladies auto-immunes affectant le système nerveux, mais la contribution exacte et les mécanismes pathogéniques spécifiques des lymphocytes T CD8[indice supérieur +] ne sont pas encore clairement établis. Le travail de recherche présenté dans cette thèse a donc permis d’établir que la lignée de souris transgénique qui exprime de façon constitutive le ligand de costimulation B7.2/CD86 sur les cellules de la microglie représente un nouveau modèle animal qui permettra d’étudier et de comprendre ces mécanismes pathogéniques spécifiques aux lymphocytes T CD8[indice supérieur +] ainsi que les processus qui régulent la participation des lymphocytes T CD8[indice supérieur +] dans la destruction de la gaine de myéline.

B lymphocytes are an important type of immune cell that contributes to pathogen clearance. When dysregulated, these cells contribute significantly to diseases such as autoimmunity, allergy and B cell cancers. Here we examine an important regulatory circuit that involves the lipid phosphatase SHIP, a key regulator of the PI3K signaling pathway. SHIP was first described as the major effector of inhibitory IgG receptor FcγRIIB, which downregulates B cell antigen receptor (BCR) signaling pathways when co-engaged. However, it is also known to inhibit signaling downstream of several other receptors, both activating and inhibitory. Here we examine the regulation and function of SHIP in B cells, focusing on the inter-related influences of binding partners, tyrosine phosphorylation and subcellular localization dynamics. First, we assess interaction of SHIP to selected candidate binding partners using an in vitro screening approach. The two most robust interactions were further characterized with respect to dissociation constant. These were: a novel interaction between SHIP phospho-Tyr944 and the SH2 domain of Nck, and a known interaction between the SH2 domain of SHIP and FcγRIIB phospho-Y292. Next, we perform the first examination of SHIP Tyr944. We provide evidence that it contributes to interaction with Nck after BCR engagement and is required for inhibition of actin turnover by SHIP. Finally, we perform the first detailed examination of the mechanisms controlling SHIP localization in human B cells stimulated through the BCR with and without co-engagement of FcγRIIB. We discover that SHIP is recruited to the plasma membrane equally in both stimulation contexts, however FcγRIIB co-ligation results in reduced mobility of SHIP molecules at the cell periphery. We identify a novel and essential role for Syk kinase in promoting SHIP membrane localization, tyrosine phosphorylation, and interaction with known binding partner Shc1. Together, these results provide significant and exploitable insight into the molecular control of a clinically important regulator of B cell responses. / February 2017

Lymphocyte activation and trafficking are indispensable to the immune system. CD44, an adhesion molecule, plays important roles in T cell activation, lymphocyte homing/trafficking, and tumor metastasis. Although the functions of CD44 have been shown in T cells and other leukocytes, little is known about its role in B cells. The effects of CD44 cross-linking on murine B cell activation via CD40L/IL-4 was explored using the anti-CD44 mAbs RK3G9 and IM7. Immobilized RK3G9 and IM7 could strongly inhibit B cell proliferation and Ig production, with IgE inhibition being prominent. Soluble anti-CD44 had no effect. The inhibitory effect of RK3G9 was not influenced by addition of anti-FCγRII, indicating no role for the inhibitory receptor. The effects of delayed addition of immobilized anti-CD44 mAbs were studied, and the results indicated no inhibition after 96 hrs of culture. B cells were also activated by either LPS or anti-IgM F(ab')2. While LPS-induced B cell activation was inhibited by immobilized anti-CD44 mAbs, anti-IgM activation was refractory. Interestingly, addition of both anti-IgM and CD40L or LPS resulted in some modulation of the inhibitory activity. Additionally, FACS and Elispot revealed that RK3G9-treated cells had reduced numbers of plasma cells. Taken together, these results suggest that CD44 cross-linking could control polyclonal B cell activation by CD40L, but allow sIgM/CD40L activation to continue.